Image Ben Hargreaves Patients Action by FDA ensures trial sponsors must consider diversity Pharma has recognised that there is a problem with diversity in clinical trials, but has so far struggled to successfully achieve real change. Market Access How the pandemic exposed faulty links in the supply chain The pandemic provided a harsh shock to healthcare, but proved particularly tough on the supply chains relied on to support public health. Patients Healthcare report finds declining public trust in institutio... There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs. Market Access Is the UK’s healthcare spending drop sustainable? The UK’s health system has been under pressure to manage costs whilst still delivering a reliable service. Load more results
Patients Action by FDA ensures trial sponsors must consider diversity Pharma has recognised that there is a problem with diversity in clinical trials, but has so far struggled to successfully achieve real change.
Market Access How the pandemic exposed faulty links in the supply chain The pandemic provided a harsh shock to healthcare, but proved particularly tough on the supply chains relied on to support public health.
Patients Healthcare report finds declining public trust in institutio... There are few things more important than health, but a recent report suggests that the public has declining trust in traditional healthcare institutions to protect theirs.
Market Access Is the UK’s healthcare spending drop sustainable? The UK’s health system has been under pressure to manage costs whilst still delivering a reliable service.
News ESC: MSD/Bayer's Verquvo disappoints in heart failure trial Bayer and MSD's hopes of expanding the use of Verquvo in heart failure have been dashed by a failed phase 3 trial.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
